Caxton Corporation’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Caxton Corporation’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-232,426	Closed	-$3.38M	–	20
2020 Q1	$3.38M	Hold	232,426	–	–	3.69%	7
2019 Q4	$2.75M	Buy	232,426 +79,688	+52%	+$1.33M	2.65%	9
2019 Q3	$3.85M	Buy	152,738 +77,143	+102%	+$2.23M	4.34%	9
2019 Q2	$1.92M	Buy	75,595 +67,674	+854%	+$2.62M	2.18%	11
2019 Q1	$337K	Buy	+7,921	New	+$179K	0.31%	14
2018 Q4	–	Sell	-3,178	Closed	-$222K	–	31
2018 Q3	$222K	Buy	3,178 +1,786	+128%	+$136K	0.21%	26
2018 Q2	$103K	Buy	+1,392	New	+$124K	0.04%	22
2015 Q3	–	Sell	-228	Closed	-$144K	–	24
2015 Q2	$144K	Buy	+228	New	+$121K	0.15%	18

Other funds holding VIRX

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Caxton Corporation's VIRX Position: Q2 2020 in Review

Caxton Corporation sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2020, closing a stake of 232,426 shares — an estimated $3.38M sold.

Caxton Corporation first reported a position in VIRX in Q2 2015 and held it in 8 quarters. The position peaked at $3.85M in Q3 2019. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2020.

Caxton Corporation reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Caxton Corporation sold 232,426 Viracta Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $3.38M.
Caxton Corporation first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2015 and held it in 8 quarters.
Caxton Corporation's Viracta Therapeutics, Inc. Common Stock position peaked at $3.85M in Q3 2019.
41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Caxton Corporation's 13F filing for Q2 2020, filed 14 Aug 2020.